Rimifin 100 mg Tablets for Dogs

País: Reino Unido

Idioma: inglés

Fuente: VMD (Veterinary Medicines Directorate)

Ingredientes activos:

Carprofen

Disponible desde:

Chanelle Pharmaceuticals Manufacturing Ltd

Código ATC:

QM01AE91

Designación común internacional (DCI):

Carprofen

formulario farmacéutico:

Tablet

tipo de receta:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapéutico:

Dogs

Área terapéutica:

Anti Inflammatory NSAID

Estado de Autorización:

Authorized

Fecha de autorización:

2007-11-08

Ficha técnica

Revised: November 2019
AN: 00625/2019
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rimifin 100 mg Tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE INGREDIENT
Carprofen
100.0 mg/tablet
EXCIPIENTS
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablet
A white to off white round shape tablets with a cross breakline on one
side.
The tablets can be divided into halves or quarters.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculo-skeletal
disorders and
degenerative joint disease. As a follow up to parenteral analgesia in
the
management of post-operative pain following soft tissue surgery.
4.3
CONTRAINDICATIONS
Do not use in cats.
Do not use in case of hypersensitivity to active substance or to any
of the
excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where
there is a possibility of gastro-intestinal ulceration or bleeding, or
where there
is evidence of a blood dyscrasia.
Refer to section 4.7.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to Sections 4.3 and 4.5
Revised: November 2019
AN: 00625/2019
Page 2 of 6
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in dogs less than 6 weeks of age, or in aged dogs, may involve
additional
risk. If such a use cannot be avoided, dogs may require careful
clinical
management. Avoid use in any dehydrated, hypovolaemic or hypotensive
dog,
as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory conditions associated with bacterial infection,
appropriate
concurrent antimicrobial therapy should be instigated.
Do not administer other NSAIDs concurrently or within 24 hours of each
other.
Some NSAIDs may be highly bound to plasma proteins and compete with
other highly b